Have you assessed how the international operations of Bio-Rad Laboratories (BIO Quick QuoteBIO - Free Report) performed in the quarter ended September 2026? For this maker of instruments used in biomedical research, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.

Our review of BIO's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

For the quarter, the company's total revenue amounted to $656.4 million, experiencing an increase of 0.5% year over year. Next, we'll explore the breakdown of BIO's international revenue to understand the importance of its overseas business operations.

A Look into BIO's International Revenue Streams

Asia accounted for 20.9% of the company's total revenue during the quarter, translating to $137 million. Revenues from this region represented a surprise of +3.62%, with Wall Street analysts collectively expecting $132.21 million. When compared to the preceding quarter and the same quarter in the previous year, Asia contributed $121.8 million (18.7%) and $121 million (18.5%) to the total revenue, respectively.

EMEA generated $231.4 million in revenues for the company in the last quarter, constituting 35.3% of the total. This represented a surprise of +11.32% compared to the $207.87 million projected by Wall Street analysts. Comparatively, in the previous quarter, EMEA accounted for $229.2 million (35.2%), and in the year-ago quarter, it contributed $222.2 million (34%) to the total revenue.

During the quarter, Other (primarily Canada and Latin America) contributed $43.2 million in revenue, making up 6.6% of the total revenue. When compared to the consensus estimate of $41.89 million, this meant a surprise of +3.13%. Looking back, Other (primarily Canada and Latin America) contributed $44.5 million, or 6.8%, in the previous quarter, and $39.8 million, or 6.1%, in the same quarter of the previous year.

International Revenue Predictions

For the current fiscal quarter, it is anticipated by Wall Street analysts that Bio-Rad will post revenues of $708.17 million, which reflects an increase of 2.2% the same quarter in the previous year. The revenue contributions are expected to be 23.2% from Asia ($164.06 million), 32.2% from EMEA ($227.79 million) and 6.1% from Other (primarily Canada and Latin America) ($42.95 million).

For the full year, a total revenue of $2.53 billion is expected for the company, reflecting a decline of 2% from the year before. The revenues from Asia, EMEA and Other (primarily Canada and Latin America) are expected to make up 20.9%, 34.4%, and 6.9% of this total, corresponding to $528.47 million, $871.66 million, and $174.44 million, respectively.

The Bottom Line

The dependency of Bio-Rad on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.

Bio-Rad, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Review of Bio-Rad Laboratories' Recent Stock Market Performance

Over the past month, the stock has seen an increase of 4.2% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 5.6%. The Zacks Medical sector, Bio-Rad's industry group, has ascended 9.4% over the identical span. In the past three months, there's been an increase of 7.1% in the company's stock price, against a fall of 4.1% in the S&P 500 index. The broader sector has increased by 8% during this interval.